Aquestive Therapeutics (AQST) Short term Debt (2018 - 2026)

Aquestive Therapeutics' Short term Debt history runs 9 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• On a quarterly basis, Short term Debt rose 50496.3% year-over-year to $13.7 million in Q1 2026; TTM through Mar 2026 was $13.7 million, a 50496.3% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, up 38338.46% from the prior year.
• Short term Debt rose to $13.7 million in Q1 2026 per AQST's latest filing, from $10.0 million in the prior quarter.
• Across five years, Short term Debt topped out at $18.7 million in Q4 2022 and bottomed at $22000.0 in Q4 2023.
• The 5-year median for Short term Debt is $6.3 million (2025), against an average of $7.2 million.
• Across the five-year window, Short term Debt sank 99.88% in 2023 and soared 50496.3% in 2026, its largest moves.
• Year by year, Short term Debt stood at $18.7 million in 2022, then sank by 99.88% to $22000.0 in 2023, then increased by 18.18% to $26000.0 in 2024, then surged by 38338.46% to $10.0 million in 2025, then jumped by 36.69% to $13.7 million in 2026.
• Per Business Quant, the three latest AQST Short term Debt figures stand at $13.7 million (Q1 2026), $10.0 million (Q4 2025), and $6.3 million (Q3 2025).